Applied DNA Sciences Inc (APDN): Price and Financial Metrics
GET POWR RATINGS... FREE!
APDN POWR Grades
- APDN scores best on the Value dimension, with a Value rank ahead of 45.36% of US stocks.
- The strongest trend for APDN is in Growth, which has been heading down over the past 159 days.
- APDN ranks lowest in Stability; there it ranks in the 4th percentile.
APDN Stock Summary
- Applied Dna Sciences Inc's market capitalization of $16,244,880 is ahead of only 2.1% of US-listed equities.
- For APDN, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for APDN comes in at -84.73% -- higher than that of only 4.77% of stocks in our set.
- Stocks that are quantitatively similar to APDN, based on their financial statements, market capitalization, and price volatility, are PHR, AUPH, ONTF, QTRX, and IMMR.
- APDN's SEC filings can be seen here. And to visit Applied Dna Sciences Inc's official web site, go to www.adnas.com.
APDN Valuation Summary
- APDN's price/sales ratio is 7.1; this is 115.15% higher than that of the median Industrials stock.
- Over the past 186 months, APDN's EV/EBIT ratio has gone up 39.7.
- Over the past 186 months, APDN's price/earnings ratio has gone up 38.2.
Below are key valuation metrics over time for APDN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
APDN | 2021-09-03 | 7.1 | 2.9 | -3.2 | -2.3 |
APDN | 2021-09-02 | 7.3 | 3.0 | -3.3 | -2.4 |
APDN | 2021-09-01 | 7.0 | 2.8 | -3.2 | -2.3 |
APDN | 2021-08-31 | 7.0 | 2.8 | -3.2 | -2.3 |
APDN | 2021-08-30 | 7.2 | 2.9 | -3.2 | -2.4 |
APDN | 2021-08-27 | 6.9 | 2.8 | -3.1 | -2.3 |
APDN Growth Metrics
- Its 5 year net income to common stockholders growth rate is now at -0.8%.
- The 2 year price growth rate now stands at -74.48%.
- Its 2 year net income to common stockholders growth rate is now at 20.07%.

The table below shows APDN's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2021-12-31 | 11.5773 | -12.93411 | -14.19865 |
2021-09-30 | 9.027738 | -13.38795 | -14.28644 |
2021-09-30 | 9.027738 | -13.38795 | -14.28644 |
2021-06-30 | 6.301992 | -11.65898 | -13.89828 |
2021-03-31 | 5.033188 | -13.41767 | -13.73874 |
2020-12-31 | 2.914119 | -12.56753 | -15.17406 |
APDN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APDN has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
- APDN's asset turnover comes in at 0.427 -- ranking 359th of 563 Business Services stocks.
- GRNQ, VOLT, and FC are the stocks whose asset turnover ratios are most correlated with APDN.
The table below shows APDN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.427 | 0.793 | -5.931 |
2021-03-31 | 0.361 | 0.820 | -6.288 |
2020-12-31 | 0.252 | 0.749 | -9.825 |
2020-09-30 | 0.163 | 0.627 | -10.610 |
2020-06-30 | 0.331 | 0.731 | -7.330 |
2020-03-31 | 0.683 | 0.796 | -6.300 |
APDN Price Target
For more insight on analysts targets of APDN, see our APDN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $17.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
APDN Stock Price Chart Interactive Chart >
APDN Price/Volume Stats
Current price | $1.27 | 52-week high | $8.10 |
Prev. close | $1.39 | 52-week low | $1.08 |
Day low | $1.23 | Volume | 32,900 |
Day high | $1.39 | Avg. volume | 79,389 |
50-day MA | $1.83 | Dividend yield | N/A |
200-day MA | $4.02 | Market Cap | 9.51M |
Applied DNA Sciences Inc (APDN) Company Bio
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes applications in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications and can be used to fortify brand protection efforts, and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide definitive real-time authentication of molecular tags in the field; and CertainT Supply Chain Platform that provides proof of product claims for materials, items, or products. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and non-diagnostic COVID-19 pooled surveillance testing to detect instances of COVID-19 in defined populations under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Latest APDN News From Around the Web
Below are the latest news stories about Applied Dna Sciences Inc that investors may wish to consider to help them evaluate APDN as an investment opportunity.
Applied DNA Announces Closing of $4.2 Million Registered Direct OfferingSTONY BROOK, N.Y., February 24, 2022--Applied DNA Announces Closing of $4.2 Million Registered Direct Offering |
Applied DNA Announces Pricing of $4.2 Million Registered Direct OfferingSTONY BROOK, N.Y., February 22, 2022--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 per share, in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million |
Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer ImmunotherapySTONY BROOK, N.Y. & ROME, February 17, 2022--First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen. |
New Strong Sell Stocks for February 15thATGE, ALGN, and APDN have been added to the Zacks Rank #5 (Strong Sell) List on February 15, 2022 |
Analysts Offer Insights on Healthcare Companies: Applied DNA Sciences (APDN), Glaukos (GKOS) and Anavex Life Sciences (AVXL)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Applied DNA Sciences (APDN – Research Report), Glaukos (GKOS – Research Report) and Anavex Life Sciences (AVXL – Research Report) with bullish sentiments. Applied DNA Sciences (APDN) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Applied DNA Sciences, with a price target of $6.00. The company's shares closed last Thursday at $3.11, equals to its 52-week low of $3.11. According to TipRanks. |
APDN Price Returns
1-mo | -31.35% |
3-mo | -55.28% |
6-mo | -73.43% |
1-year | -78.87% |
3-year | -94.31% |
5-year | -97.76% |
YTD | -68.41% |
2021 | -21.18% |
2020 | 21.72% |
2019 | -73.81% |
2018 | -74.84% |
2017 | -14.05% |
Continue Researching APDN
Want to see what other sources are saying about Applied Dna Sciences Inc's financials and stock price? Try the links below:Applied Dna Sciences Inc (APDN) Stock Price | Nasdaq
Applied Dna Sciences Inc (APDN) Stock Quote, History and News - Yahoo Finance
Applied Dna Sciences Inc (APDN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...